TheraRadar
← Back
Data updated: Jun 28, 2026

INTRABIO

Pharma
Neurology Execution: Needs Improvement

INTRABIO is a pharmaceutical company focused on Neurology. Key products include AQNEURSA.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2024)
1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2024 AQNEURSA (LEVACETYLLEUCINE) First-in-Class · Orphan · Priority Review · Fast Track

Upcoming FDA Decisions

Full Calendar →
Sep 19, 2026 — AQNEURSA (levacetylleucine)

INTRABIO's Key Drugs

INTRABIO's core commercial portfolio centers on AQNEURSA, spanning Neurology — its most strategically important drugs approved in the last 15 years.

AQNEURSA
CNS

Niemann-Pick Disease Type C

Approved 2024

INTRABIO's Recent FDA Approvals

INTRABIO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

AQNEURSA NDA
2024-09-24
levacetylleucine
Niemann-Pick Disease Type C

INTRABIO's Therapeutic Areas

INTRABIO's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
0 drugs Phase 3: 1

INTRABIO's Top Competitors

INTRABIO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Neurology
AbbVie big-pharma
Neurology
Eli Lilly big-pharma
Neurology
Roche big-pharma
Neurology
Bristol-Myers Squibb big-pharma
Neurology

INTRABIO Pipeline Snapshot

INTRABIO has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.

1
Phase 3
0
Phase 2
0
Phase 1

Phase 3 Readout Calendar Pro

3 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2027
N-Acetyl-L-Leucine
CACNA1A
Estimated · fresh NCT07221292
Q4 2027
N-Acetyl-L-Leucine
Ataxia-Telangiectasia
Estimated · aging NCT06673056
Q2 2030
N-Acetyl-L-Leucine
Niemann-Pick Disease, Type C
Estimated · fresh NCT05163288

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • AQNEURSA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Neurology pipeline focus
  • • 3 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/3 completed
  • • Speed: 44 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges